| 1948 | Riken reorganized into Kagaku-Kenkyusho Launched "Penicillin Kaken" |
|---|---|
| 1950 | Launched "Streptomycin Kaken" |
| 1952 | Kagaku-Kenkyusho renamed Kaken Chemicals |
| 1953 | Launched "Athletan" (anti-trichophyton product) |
| 1962 | Kaken Chemicals listed on the First Section of the Tokyo Stock Exchange |
| 1963 | Completed Shizuoka Factory |
| 1965 | Received the 11th Okochi Memorial Prize |
| 1971 | Received the 17th Okochi Memorial Prize |
| 1982 | Kaken Chemicals merged with Kakenyaku-Kako to form KAKEN PHARMACEUTICAL CO., LTD. |
| 1987 | Launched "Artz" (anti-osteoarthritis agent) |
| 1988 | Kaken Pharma Co., Ltd. established Launched "Adofeed" |
| 1989 | Launched "Ebrantil" (anti-dysuria agent) |
| 1992 | Launched "Procylin" Launched "Mentax" |
| 1993 | Launched "Artz Dispo" (anti-osteoarthritis agent) |
| 1994 | Received the 40th Okochi Memorial Prize |
| 1995 | Received the 41st Okochi Memorial Prize |
| 1996 | Mentax approved by U.S. Food and Drug Administration |
| 1998 | Completed Bunkyo Green Court Launched "Seprafilm" (post-operative adhesion barrier) |
| 2000 | Won the fiscal 2000 3Rs (Reduce, Reuse and Recycle) Promotion Merit Award and the Minister of Health and Welfare Award |
| 2001 | ISO14001 obtained in Shizuoka site Launched "Fiblast Spray" (wound-healing agent) |
| 2004 | Launched "Mentax Spray" |
| 2005 | Obtained the rights to develop, manufacture and sell bFGF globally |
| 2006 | Out-licensed antifungal compound “KP-103” in North America and Europe |
| 2007 | Launched "Berasus" |
| 2011 | Launched "Lipidil" |
| 2014 | Launched "Clenafin" (onychomycosis treatment) |
| 2015 | In-licensed "BBI-4000" in Japan and certain other Asian countries |
| 2016 | Acquired exclusive rights to develop and distribute "NexoBrid" in Japan Out-licensed "Clenafin" in South Korea Launched "Regroth dental kit" (periodontal regenerative agent) |
| 2017 | Launched collaborative research with Numab Therapeutics AG to develop a new antibody drug Out-licensed "Clenafin" in Taiwan |
| 2018 | Launched "Hernicore" (lumbar disc herniation treatment) Out-licensed "Clenafin" in Hong Kong and Macau |
| 2019 | Acquired exclusive rights to distribute "Lenabasum" (systemic sclerosis and dermatomyositis treatment) in Japan Out-licensed "Clenafin" in China Acquired exclusive rights to develop and distribute "Ivermectin lotion 0.5% (head lice treatment) in Japan |
| 2020 | Launched "Ecclock" Gel 5% (primary axillary hyperhidrosis treatment) |
| 2021 | Out-licensed "Clenafin" in Europe Acquired ARTham Therapeutics Inc. and made it a subsidiary |
| 2023 | ・Acquired exclusive rights to develop and distribute "Seladelpar" (Primary biliary cholangitis treatment) in Japan ・Acquired exclusive rights to develop and distribute "Tildacerfont" (Congenital adrenal hyperplasia treatment) in Japan |
| 2024 | ・Acquired marketing authorization for “Merislon” (dizziness and equilibrium disorder treatment) and "Mional"(muscle relaxant) from Eisai Co., Ltd. ・Concluded an agreement for the transfer of intellectual property rights and a marketing alliance option for "NM26" (atopic dermatitis treatment). ・Acquired exclusive domestic marketing rights for "Silk Elastin Wound Sheet" (wound dressing). ・Entered into a joint research agreement for "ND081" (inflammatory bowel disease treatment). ・Acquired Aadi Subsidiary, Inc. (now Aadi Bioscience, Inc.) and its product "FYARRO" (acquisition completed in March 2025). ・Signed a license agreement for a STAT6 inhibitor (oral treatment for Type 2 inflammatory diseases such as atopic dermatitis and asthma). ・Acquired exclusive domestic rights for development, manufacturing, and marketing of "ESK-001" (TYK2 inhibitor for psoriasis vulgaris, etc.). ・Obtained marketing authorization for “Clenafin” in Italy. |
| 2025 | ・Entered into a license agreement for "gMSC1" (allogeneic synovial mesenchymal stem cell-derived 3D artificial tissue). ・Acquired development and marketing rights in Japan for "navenibart“ a long-term prophylactic treatment for hereditary angioedema (HAE). ・Launched the Authorized Generic (AG) of “Clenafin“. ・Received both the "Licensing Deal of the Year" and "Pharma Company of the Year" at the Citeline Japan Awards 2025. ・Commenced co-development for "NM81“(formerly ND081), an inflammatory bowel disease treatment. ・Launched “ECCLOCK” in South Korea. ・In-licensed and launched "EKTERLY" (an oral plasma kallikrein inhibitor for the treatment of acute attacks of HAE) . |